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Uveal melanoma cells use ameboid and 
mesenchymal mechanisms of cell motility 
crossing the endothelium
ABSTRACT Uveal melanomas (UMs) are malignant cancers arising from the pigmented layers 
of the eye. UM cells spread through the bloodstream, and circulating UM cells are detectable 
in patients before metastases appear. Extravasation of UM cells is necessary for formation of 
metastases, and transendothelial migration (TEM) is a key step in extravasation. UM cells 
execute TEM via a stepwise process involving the actin-based processes of ameboid blebbing 
and mesenchymal lamellipodial protrusion. UM cancers are driven by oncogenic mutations 
that activate Gαq/11, and this activates TRIO, a guanine nucleotide exchange factor for RhoA 
and Rac1. We found that pharmacologic inhibition of Gαq/11 in UM cells reduced TEM. Inhi-
bition of the RhoA pathway blocked amoeboid motility but led to enhanced TEM; in contrast, 
inhibition of the Rac1 pathway decreased mesenchymal motility and reduced TEM. Inhibition 
of Arp2/3 complex allowed cells to transmigrate without intercalation, a direct mechanism 
similar to the one often displayed by immune cells. BAP1-deficient (+/–) UM subclones dis-
played motility behavior and increased levels of TEM, similar to the effects of RhoA inhibitors. 
We conclude that RhoA and Rac1 signaling pathways, downstream of oncogenic Gαq/11, 
combine with pathways regulated by BAP1 to control the motility and transmigration of 
UM cells.
INTRODUCTION
Uveal melanoma (UM) is a highly aggressive cancer arising in the 
uveal layers of the eye, including the choroid, ciliary bodies, and iris. 
The eye is the second most common site of melanoma. UM and 
cutaneous melanoma are distinct diseases (van der Kooij et al., 
2019; Urtatiz et al., 2020). Oncogenesis of UM tumors is driven by 
constitutive activation of the Gq family of alpha subunits, Gαq and 
Gα11 (GNAQ and GNA11) in over 90% of tumors, while cutaneous 
melanomas are driven by BRAF and NRAS mutations (Van Raams-
donk et al., 2009, 2010). Ten-year survival of patients with primary 
UM tumors is about 50%, compared with over 90% for cutaneous 
melanoma (Carvajal et al., 2017). Despite local control of the 
primary eye tumor being achieved in over 95% of patients, UM has 
a high rate of metastasis and lethal outcome (Krantz et al., 2017). 
The anatomy of the eye essentially prevents local spread, and the 
posterior chamber of the eye lacks lymphatic vessels, so metastatic 
spread of UM to distant organs occurs only through the blood-
stream (Clarijs et al., 2001).
Hematogenous spread of UM cells begins with shedding of cells 
from the primary eye tumor. The tumor vasculature of UM is irregular 
and discontinuous, providing a poor barrier to cell shedding (Clarijs 
et al., 2002; Mihic-Probst et al., 2012). As a result, circulating tumor 
cells are found in all patients, even those with low-risk tumors that 
do not develop metastatic disease (Keilholz et al., 2004; Callejo 
et al., 2006; Anand et al., 2019). Because shedding of cells into the 
blood is common, extravasation of circulating tumor cells out of 
blood vessels at distant sites may be a key rate-limiting step for UM 
metastasis.
To investigate transendothelial migration (TEM), we developed a 
cell culture system employing primary human endothelial monolay-
ers grown on polyacrylamide hydrogels, and we followed TEM in 
real time with living cells (Onken et al., 2014b). Using this approach, 
we discovered that the migration of UM cells occurs via a stepwise 
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process (Onken et al., 2014a). Suspended UM cells attach to endo-
thelial cells and then intercalate between adjacent endothelial cells, 
flattening into the monolayer. UM cells remain intercalated for up to 
several hours before releasing from the endothelial monolayer and 
migrating underneath it. The cellular and molecular mechanisms 
driving each step have not been characterized and may provide in-
formation for preventing circulating tumor cells from exiting the 
vasculature.
Cell migration and the actin cytoskeleton are key features of 
UM metastasis. Spread of UM tumors to distant organs is known to 
be promoted by loss of BAP1, a chromatin remodeling factor 
(Harbour et al., 2010), and we found that depletion of BAP1 in-
creases the overall rate of TEM in our system (Onken et al., 2014a). 
BAP1 is a histone deubiquitinase recruited to promoters of genes 
(Yen et al., 2018), and we found that several actin cytoskeleton 
regulator genes are targeted by BAP1 in UM cells (Yen et al., 
2018). In parallel, constitutively active Gq/11, the oncogenic driver 
of UM, activates the dual nucleotide exchange factor TRIO, which 
in turn activates the Rho-like small GTPases RhoA and Rac1 
(Schmidt and Debant, 2014) that regulate the actin cytoskeleton 
during cell migration (Feng et al., 2014, 2019). We hypothesize 
that regulation of actin-based processes, downstream of BAP1 
and Gq/11, and via the RhoA and Rac1 pathways, controls the 
migration of UM cells.
Rac1 drives actin polymerization at the leading edge of a migrat-
ing cell and promotes focal complex assembly (Nobes and Hall, 
1995; Parri and Chiarugi, 2010), resulting in the formation of lamel-
lae and lamellipodia, which move the cell forward (Nobes and Hall, 
1995, 1999; Parri and Chiarugi, 2010). Cell movement based on 
Rac1-driven lamellipodial protrusions is often referred to as “mesen-
chymal” motility (Cooper et al., 2015; Byrne et al., 2016). Rac1 acti-
vates downstream effectors, including WAVE2, which activate 
Arp2/3 complex for branched actin polymerization (Haga and Rid-
ley, 2016). Rac1 also activates p21-activated kinase (PAK), which has 
several important substrates (Bokoch, 2003; Zhao and Manser, 
2012), including GEF-H1, a regulator of RhoA (Guilluy, Garcia-Mata, 
and Burridge, 2011).
RhoA activates Rho-associated protein kinases 1 and 2 (ROCK1 
and ROCK2) (Sanz-Moreno et al., 2008; Acton et al., 2014), which 
increase actomyosin contractility via myosin light-chain (MLC) 
phosphorylation. This results in increased cortical contractile 
forces, which enhance membrane blebbing (Chrzanowska-Wod-
nicka and Burridge, 1996). Cell movement based on RhoA-driven 
contractile blebbing is often referred to as “amoeboid” motility 
(Cooper et al., 2015; Byrne et al., 2016). Biochemically, the RhoA 
and Rac1 pathways can be antagonistic, with opposing roles in 
cell migration (Sanz-Moreno et al., 2008; Guilluy et al., 2011). 
ROCK signaling can antagonize Rac1 via ARHGAP22, and Rac1-
WAVE2 activity can antagonize ROCK signaling (Sanz-Moreno 
et al., 2008). Interacting and antagonistic pathways downstream 
of RhoA and Rac1 control switching between amoeboid and mes-
enchymal migration and have been identified in 2D and 3D cul-
ture conditions in normal fibroblasts and melanoma and breast 
cancer cells (Cooper et al., 2015; Sander et al., 1999; Byrne et al., 
2016).
Here, we investigated the roles of these signaling pathways with 
a combination of pharmacologic and molecular genetic perturba-
tions, using direct live-cell observation of TEM. We found that UM 
cells in suspension show predominantly amoeboid motility driven 
by the RhoA pathway and that UM cells switch from amoeboid mo-
tility to mesenchymal motility as they adhere to and migrate through 
the endothelial monolayer.
RESULTS
First, we established methods to quantify UM cell behavior during 
TEM, allowing us to measure the effects of pharmacologic and ge-
netic perturbations. We characterized the movements of two UM 
cell lines, 92.1 and Mel202, before and during TEM from live-cell 
movies (Figure 1A and Supplemental Video S1). UM cells displayed 
amoeboid blebbing while in suspension, immediately after addition 
to endothelial monolayers, and for a short while after coming to rest 
on the monolayers. The cells continued blebbing during their initial 
interactions with the endothelial monolayer. Next, they stopped 
blebbing and formed lamellipodial protrusions. The cells proceeded 
to spread, flatten, and intercalate themselves between endothelial 
cells. The steps of adhesion and intercalation occurred relatively 
quickly and were complete within a few hours. After a longer time, 
the cells formed new lamellipodial protrusions that extended under-
neath the endothelial monolayer, and the cells migrated away, in 
agreement with our previous observations (Onken et al., 2014a).
We quantified the progression of UM cells through each of these 
steps during TEM (see Figure 1B for an example) by measuring and 
calculating the following parameters: 1) total number of cells com-
pleting each step after 2 h (Figure 1C), 2) maximum instantaneous 
rate of cells completing each step (Figure 1D), and 3) time required 
for half the expected number of cells to complete each step (Figure 
1E). The endothelial monolayers were prepared from primary hu-
man dermal microvascular endothelial cells (HDMVECs), for which 
different lots display a certain level of biological variability. To ac-
count for this variability among lots, control (DMSO-treated) cell 
samples were produced with every experiment, and the results from 
these control samples were used to normalize the results from ex-
perimental samples.
Inhibition of the oncogenic driver Gq/11 blocks 
transendothelial migration
Constitutively activating mutations in Gq/11 are the driving onco-
genes for over 90% of UM tumors (Moore et al., 2016). Gq/11 acti-
vates the dual-GEF TRIO, which activates RhoA and Rac1 in UM cells 
(Feng et al., 2014). We used FR900359, a potent inhibitor of Gq/11 
in UM cells (Onken et al., 2018), to block TRIO activation by Gq. UM 
cells treated with FR900359 for 24 h showed significant decreases in 
progression for all steps of transmigration (Figure 1A and Supple-
mental Video S1). Adhesion and intercalation were reduced to 40% 
of untreated activity, and neither extension nor migration was de-
tected during any 2-h experiment (Figure 1C). Maximum rates of pro-
gression of each step decreased by >4-fold (Figure 1D), and time to 
reach maxima increased by >2-fold (Figure 1E). Thus, inhibition of the 
oncogenic driver mutation blocks most UM cells from transmigrating 
and slows the progression of the few cells that do transmigrate.
Inhibition of the RhoA pathway increases transendothelial 
migration
Activated TRIO regulates both RhoA and Rac1, which control op-
posing cell morphology pathways (Sanz-Moreno et al., 2008). We 
interrogated each pathway independently to dissect their regula-
tory roles in UM cells during TEM. Inhibition of ROCK, the immedi-
ate downstream effector of activated RhoA, by Y-27632 blocked the 
amoeboid blebbing activity of UM cells in suspension and on the 
surface of the monolayers (Figure 2A and Supplemental Video S2). 
Surprisingly, UM cells treated with Y-27632 showed significant in-
creases in both the percentage of cells completing each step of 
TEM (Figure 2B) and the rates of cells progressing through each 
step (Figure 2, C and D). To confirm that these results were specific 
to the Rho pathway and not caused by off-target effects of the 
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inhibitor, we expressed a dominant-negative form of RhoA. For both 
UM cell lines dominant-negative RhoA expression caused increases 
in TEM similar to the effects of Y-27632 treatment (Figure 2, B–D).
Downstream of ROCK in the RhoA pathway is nonmuscle myosin 
II, the motor protein that powers cellular contractility and mem-
brane tension and thus drives amoeboid blebbing (Wyckoff et al., 
2006). Inhibition of nonmuscle myosin II in UM cells by treatment 
with blebbistatin blocked blebbing activity (Figure 2A and Supple-
mental Video S2) and increased the rate of TEM (Figure 2, B–E). 
These effects were similar to those of Y-27632. Thus, the effects of 
ROCK inhibition on UM cells appear to occur through regulation of 
actomyosin contractility.
FIGURE 1: Quantification of TEM of untreated and FR900359-treated UM cells. (A) Frames from 
representative movies of TEM by control 92.1 UM cells (upper panels and Supplemental Video 
S1) and 92.1 cells treated with FR900359 (lower panels), at 20-min intervals. Scale bar = 50 µm. 
(B) Cumulative percentage of cells undergoing each step of UM cell transmigration. Results are 
from three 2-h movies for each condition for each cell line. The total numbers of 92.1 cells 
scored were 321 (vehicle) and 486 (FR900359); the total numbers of Mel202 cells scored were 
365 (vehicle) and 252 (FR900359). Curves from both cell lines under control and treated 
conditions were quantified to generate the bar graphs in panels C-E (*p < 0.01). (C) Endpoint 
values for each step after 2 h. (D) Maximum rate of each step calculated from the slope of the 
tangent at the inflection point. (E) Time to reach half of the calculated maximum plateau for 
each step.
Inhibition of the Rac1 pathway blocks 
transendothelial migration
Actin-based lamellipodial protrusions are a 
prominent feature of UM cells as the cells 
intercalate into the endothelial monolayer 
and then extend below the monolayer and 
migrate underneath it. We hypothesized 
that these protrusions were driven by acti-
vation of Rac1. To inhibit Rac1, we treated 
UM cells with NSC-23766, which blocks the 
activation of Rac1 by exchange factors. 
The cells showed increased amoeboid 
blebbing and decreased lamellipodial pro-
trusion, with an overall impairment of TEM 
(Figure 3 and Supplemental Video S3). The 
numbers of cells completing each step 
were significantly reduced, as were the 
rates of completion within each step 
(Figure 3, B–D). To confirm that these re-
sults were specific to the Rac pathway and 
not caused by off-target effects of the in-
hibitor, we expressed a dominant-negative 
form of Rac1 in both UM cell lines. Mel202 
UM cells expressing dominant-negative 
Rac1 showed significant reduction of all 
steps of TEM, similar to the effects of NSC-
23766 treatment. The effect on 92.1 cells 
was a significant increase in the time for 
completing each step (Figure 3, B–D). 
Taken together, these decreases in TEM 
parameters were similar to the stronger ef-
fects observed for cells treated with 
FR900359 above (Figure 1, C–E).
Rac1 directly activates PAKs, which phos-
phorylate target proteins (Zhao and Manser, 
2012). Treatment of UM cells with the PAK 
inhibitor IPA-3 enhanced blebbing and re-
duced TEM (Figure 3, A and B), similarly to 
NSC-23766. Fewer cells completed each 
step, and rates of completion within each 
step were reduced (Figure 3, C–E). Interest-
ingly, UM cells treated with either NSC-
23766 or IPA-3 also showed larger blebs 
and increased extracellular debris (Figure 
3A and Supplemental Video S3) compared 
with untreated cells (Figure 1A and Supple-
mental Video S1), suggesting dysregulation 
of bleb size and retraction resulting from in-
hibition of the Rac pathway.
Inhibition of Arp2/3 complex: uveal melanoma cells 
transmigrate and bypass intercalation
The actin-based protrusions that occur during lamellar and lamelli-
podial cell migration are driven by the rapid formation and growth 
of branched actin networks at the cell periphery. Actin branching is 
nucleated by the Arp2/3 complex, which is activated by the WAVE 
complex, a downstream target of activated Rac1. We used the 
Arp2/3 inhibitor CK-666 (Nolen et al., 2009) to interrogate the role 
of branched actin formation in Rac1 regulation of TEM. UM cells 
treated with CK-666 showed extensive blebbing, similar to the 
effects of NSC-23766 and IPA-3 (Figure 4A and Video S4). The 
CK-666–treated cells failed to switch from amoeboid blebbing to 
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mesenchymal motility; however, they proceeded to perform TEM, 
using a direct manner that bypassed the process of intercalation 
(Figure 4A and Supplemental Video S4). This TEM migration behav-
ior is similar to that displayed by immune cells, including lympho-
cytes and NK cells (Onken et al., 2014b).
Depletion of the metastasis suppressor BAP1 increases 
transendothelial migration
Loss of the chromatin-remodeling factor BAP1 drives metastasis in 
UM tumors (Harbour et al., 2010; Matatall et al., 2013). BAP1 is en-
riched at the transcriptional promoters of TRIO, cortactin, and sev-
eral GTPase activating proteins (GAPs) and guanine nucleotide ex-
change factors (GEFs) in UM (Supplemental Figure S1A; Yen et al., 
2018), and several of these BAP1 targets are differentially regulated 
in BAP1-deficient class 2 UM tumors (Supplemental Figure S1B; 
Onken et al., 2004), which could alter the balance of RhoA and Rac1 
pathways. We used CRISPR/Cas9 genome editing to generate 
BAP1-deficient UM cells. The homozygous loss of BAP1 was lethal 
in all of several UM cell lines tested, consistent with previous studies 
(Testa et al., 2011; Dey et al., 2012; Matatall et al., 2013; Hart et al., 
FIGURE 2: Effects of Rho pathway inhibition on TEM of UM cells. (A) Frames from 
representative movies of TEM by 92.1 UM cells treated with RhoA-dependent ROCK1 inhibitor 
Y-27632 (upper panels and Supplemental Video S2) or myosin inhibitor blebbistatin (lower 
panels), at 20-min intervals. (B) Endpoint values of cells that have undergone each step of UM 
cell transmigration treated with Y-27632 or blebbistatin, or expressing dominant negative RhoA, 
based on results from three 2-h movies for each condition for each cell line. The total numbers 
of 92.1 cells scored were 355 (vehicle), 502 (Y-27632), 285 (blebbistatin), and 103 (RhoA-DN); the 
total numbers of Mel202 cells scored were 569 (vehicle), 172 (Y-27632), 700 (blebbistatin), and 
151 (RhoA-DN). (C) Maximum rates for each step of TEM. (D) Times to reach half of the 
calculated maximum plateaus. Inhibition of the Rho pathway causes more UM cells to 
transmigrate and at a faster rate. Scale bar, 50 µm; *p < 0.01.
2015). However, we were able to generate 
two independent BAP1-deficient heterozy-
gous subclones of the 92.1 UM cell line, 
92.1-1D7 and 92.1-2D3. Both cell lines dis-
played amoeboid blebbing while in suspen-
sion, and they switched to forming lamelli-
podial protrusions during intercalation, 
extension, and migration, similar to parental 
BAP1(+/+) cells (Figure 5A and Supplemen-
tal Video S5). However, in contrast to paren-
tal BAP1 (+/+) cells, both BAP1 (+/–) sub-
clones showed quantitative increases in all 
steps of TEM. More cells completed all 
steps, and the times for initiation and inter-
calation were shorter (Figure 5, C–E). Thus, 
reduction of BAP1 activity produced effects 
on TEM similar to those resulting from inhi-
bition of the RhoA pathway, as opposed to 
the effects of inhibition of the Rac1 pathway 
(Supplemental Figure S2). These results sug-
gest that BAP1 expression favors activation 
of the RhoA pathway over the Rac1 path-
way, such that loss of BAP1 shifts the bal-
ance toward Rac1-driven motility and in-
creased TEM.
DISCUSSION
Uveal melanoma cells switch modes of 
motility during transendothelial 
migration
UM cells perform TEM by a stereotypical 
multistep route, which includes intercalation 
of the UM cell into the endothelial mono-
layer (Onken et al., 2014a). Here, we discov-
ered that UM cells exhibit both amoeboid 
and mesenchymal modes of motility as they 
migrate through the endothelium during 
TEM and that the switch from amoeboid to 
mesenchymal motility is an essential ele-
ment of intercalation. Previous studies re-
ported amoeboid and mesenchymal mor-
phologies for cutaneous melanoma cells 
attached to substrates with varying levels of adhesivity (Friedl and 
Wolf, 2003; Sahai and Marshall, 2003; Sanz-Moreno et al., 2008, 
2011); those studies did not involve melanoma cells interacting with 
the endothelium.
We discovered that the oncogenic driver mutation of UM cells is 
responsible for promoting TEM. Inhibition of constitutively active 
Gq/11 in UM cells, by the pharmacologic inhibitor FR900359, led to 
a nearly complete loss of TEM activity in our assay system. In our 
previous work, FR900359 caused UM cells to stop dividing and to 
re-differentiate towards their melanocytic state (Onken et al., 2018). 
Together, the results suggest that FR900359 has promise as a novel 
therapeutic agent for UM tumors. The inhibition of TEM observed 
here may be particularly significant because the lethality of UM tu-
mors is due to metastasis through the bloodstream (Anand et al., 
2019; Clarijs et al., 2001) and thus requires TEM.
We discovered that the Rho and Rac pathways activated down-
stream of the oncogenic mutation in UM cells have distinct and 
complementary roles in the mechanism of transmigration. Inhibit-
ing the Rho pathway blocked amoeboid motility but increased 
TEM (Supplemental Figure S2), while inhibiting the Rac pathway 
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blocked mesenchymal motility and decreased TEM (Supplemental 
Figure S2).
We propose the following model of TEM regulation in UM cells, 
illustrated in Figure 6 and Supplemental Figure S3. First, UM cells 
display amoeboid morphology and motility as they flow through the 
bloodstream and make initial contact with the endothelium. This 
amoeboid behavior depends on active RhoA and actomyosin con-
traction. Following contact with the endothelium, UM cells convert 
their morphology and motility to lamellar and lamellipodial protru-
sions driven by Rac1. These protrusive actions enhance the interac-
tions of UM cells with the endothelial cells, which allows the UM cells 
to intercalate and flatten into the endothelium and then ultimately 
leave the endothelium and migrate into surrounding tissues.
Amoeboid and mesenchymal migration: complementary 
roles for transendothelial migration
UM cells treated with Arp2/3 complex inhibitor interacted with the 
endothelial monolayer and performed TEM, but the cells did not 
switch from the amoeboid mode to the mesenchymal mode of mo-
FIGURE 3: Effects of Rac pathway inhibition on TEM of UM cells. (A) Frames from 
representative movies of TEM by 92.1 UM cells treated with the RacGEF inhibitor NSC-23766 
(upper panels and Supplemental Video S3) and the PAK inhibitor IPA-3 (lower panels). 
(B) Endpoint values of cells treated with NSC-23766 or IPA-3, or expressing dominant negative 
Rac1, that have undergone each step based on results from three 2-h movies for each condition 
for each cell line. The total numbers of 92.1 cells scored were 402 (vehicle), 297 (NSC-23766), 
259 (IPA-3), and 138 (Rac1-DN); the total numbers of Mel202 cells scored were 641 (vehicle), 
271 (NSC-23766), 417 (IPA-3), and 195 (Rac1-DN). (C) Maximum rates for each step. The number 
of TEM events was too low to calculate maximum rates of migration. (D) Times to reach half of 
the calculated maximum plateaus. Inhibition of the Rac pathway caused fewer UM cells to 
transmigrate and at a slower rate. The number of TEM events was too low to analyze extension 
and migration accurately. Scale bar, 50 µm; *p < 0.01.
tility and migration. In this case, the interca-
lation step was dispensable for TEM, and 
the amoeboid mode of behavior alone was 
sufficient. This finding suggests that UM 
cells in situ may use a combination of amoe-
boid and mesenchymal modes of migration, 
depending on the local circumstances, such 
as the architecture of the vascular bed and 
the flow of the bloodstream. One might 
speculate that inside-out signaling from Rac 
and PAK activates adhesion molecules on 
the UM cell surface, such as integrin α4β1 
(Rullo et al., 2012), required for adhesion to 
endothelial cells (Onken et al., 2014a). This 
hypothesis is supported by our observation 
of decreased interactions of Rac/PAK-inhib-
ited UM cells with the endothelial cell 
monolayer, compared with untreated or 
Arp2/3-inhibited UM cells.
Another possible explanation for the ef-
fect of Arp2/3 complex inhibition is a re-
quirement for branched actin assembly to 
stabilize early interactions that promote the 
maturation of adhesive junctions. One 
model of cell–cell adhesion formation is that 
weak interactions at a small cell–cell contact 
surface recruit active Rac1, which activates 
actin assembly to expand the contact sur-
face and form a mature adhesion (Collins 
and Nelson, 2015). This model is based on 
observations that Arp2/3 complex inhibition 
disrupts junction formation between cells 
on plastic but not the formation of cell ag-
gregates (Collins and Nelson, 2015). Cells 
that aggregate with neighboring cells do 
not require extensive Arp2/3-dependent la-
mellipodia activity, but cells that are flat and 
spread out require expanded contacts 
through lamellipodia, which would require 
Arp2/3 activity (Collins et al., 2017). This 
model predicts that blocking branched actin 
formation by inhibiting Rac1 or PAK would 
also prevent UM cells from establishing suf-
ficiently strong adhesions with the endothelial monolayer. Our re-
sults expand this view by suggesting that separate adhesive mecha-
nisms exist, dependent on and independent of stabilization by actin 
assembly during TEM.
Metastasis-promoting BAP1 mutation favors mesenchymal 
motility and increases transmigration
We discovered that partial loss of BAP1, based on heterozygous 
gene deletion, caused increases in all steps of TEM. This discovery is 
important because in human UM patients, the loss of BAP1 is the key 
genetic feature associated with a high risk of metastasis in the class 2 
lethal genotype (Harbour et al., 2010; Matatall et al., 2013). The clini-
cal relationship of deletion of BAP1 to metastatic spread is consistent 
with the biological connection of BAP1 function with the mechanism 
of TEM discovered here. The genomic transcriptional targets of BAP1 
include a number of actin cytoskeleton genes, including TRIO, cor-
tactin, and various GAPs and GEFs (Figure S1A) (Yen et al., 2018). 
BAP1 targets of particular note include ARHGAP18, a Rho-specific 
GAP, and ARHGEF4, a Rac/cdc42-specific GEF (Yen et al., 2018), 
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both of which are up-regulated in BAP1-deficient Class 2 human 
tumors (Onken et al., 2004; Supplemental Figure S1B). Concurrent 
up-regulation of ARHGAP18 and ARHGEF4 would be expected to 
decrease RhoA signaling and increase Rac1 signaling and promote 
TEM. In support of this hypothesis, increased expression of ARH-
GAP18 (Maeda et al., 2011; Humphries et al., 2017) and ARHGEF4 
(Taniuchi et al., 2018) has been linked to metastasis in other cancers.
MATERIALS AND METHODS
Request a protocol through Bio-protocol.
Reagents and inhibitors
Chemicals and reagents were obtained from Fisher Scientific (Pitts-
burgh, PA) or Sigma-Aldrich (Saint Louis, MO), except as follows: 
Blebbistatin, Y-27632, NSC-23766, and IPA-3 were from Selleck 
Chemicals (Houston, TX). FR900359 was prepared as described by 
Onken et al. (2018). Inhibitors were dissolved in DMSO as stock solu-
tions and frozen in small aliquots. For TEM experiments, Blebbistatin 
and Y-27632 were used at 10 µM, IPA-3 was used at 30 µM, CK-666 
was used at 100 µM, and FR900359 was used at 100 nM. Inhibitors 
were tested for cell toxicity using a tetrazolium-based Cell Counting 
Kit-8 (Bimake, Houston, TX), with treatment at working concentra-
tions for 12 h. In these assays, the inhibitors did not significantly re-
duce cell viability, with the exception of FR900359, which has long-
term effects that have been described elsewhere (Onken et al., 2018).
FIGURE 4: Effects of Arp2/3 complex inhibition on TEM of UM cells. (A) CK-666 blocked the 
switch to lamellipodial activity, decreasing intercalation (upper panels and Supplemental Video 
S4) and increasing direct transmigration bypassing intercalation (lower panels). (B) Endpoint 
values of cells that have undergone each step of transmigration based on results from three 2-h 
movies for each condition for each cell line. The total numbers of 92.1 cells scored were 321 
(vehicle) and 360 (CK-666); the total numbers of Mel202 cells scored were 365 (vehicle) and 632 
(CK-666). (C) Maximum rates were decreased for intercalation but increased for migration. 
(D) Times to reach half of the calculated maximum plateaus. Scale bar, 50 µm; *p < 0.01.
Cell lines, plasmids, and viruses
Cells were cultured at 37°C in a humidified 
5% CO2 incubator. Human 92.1 UM cells 
(RRID: CVCL_8607) were the generous gift 
of Martine Jager (Laboratory of Ophthal-
mology, Leiden University, Netherlands) and 
were grown in RPMI 1640 medium (Life 
Technologies, Carlsbad, CA) supplemented 
with 10% FBS and antibiotics. Primary hu-
man dermal microvascular endothelial cells 
(HDMVECs: HMVEC-dNeo, Catalog #CC-
2516; Lonza, Allendale, NJ) were grown in 
EGM-2 MV culture medium (Lonza). HDM-
VECs were not used after eight passages. 
BAP1(+/–) 92.1 subclone cell lines were gen-
erated using CRISPR/Cas9 genome editing 
and sequence-verified by the Washington 
University Genome Engineering and iPSC 
Center (http://geic.wustl.edu). Briefly, single 
guide RNAs were used to target Cas9 to 
exon 3 of BAP1 in 92.1 cells to generate 
frameshifted truncation mutants. The 1D7 
strain is heterozygous for a 53-bp deletion: 
p.V24fsX26 (c.183–237 delGTCAAGGGGG-
T G C A A G T G G A G G A G AT C TA C G A -
CCTTCAGAGCAAATGTCAGGG) (Supple-
mental Figure S4). The 2D3 strain is 
heterozygous for a 43-bp deletion: 
p.K25fsX32 (c. 186–230 delAAGGGGGTGC
AAGTGGAGGAGATCTACGACCTT-
CAGAGCAAAT; Supplemental Figure S4).
Lentiviral-based constructs were used for 
cell expression experiments. The pSLIK-DN-
RhoA(T19N) dominant-negative YFP-fusion 
expression construct was a gift from 
Sanjay Kumar (Addgene plasmid #84646; 
RRID:Addgene_84646; MacKay and Kumar, 
2014). Viral production and infections were carried out according to 
consortium recommendations (https://www.broadinstitute.org/rnai-
consortium/) using HEK293T cells transfected with third-generation 
lentivirus packaging plasmids, pMDLg/pRRE, pRSV-Rev, and 
pMD2.G, using TransIT-LT1 transfection reagent (MirusBio, Wiscon-
sin). Lentivirus supernatants were filtered with a 0.45-µm pore filter 
(EMD Millipore Corp, USA) and concentrated at 20,000 rpm for 2 h. 
Lentiviral particles were resuspended and stored in aliquots at 
–70°C. For protein expression, lentivirus was added directly to UM 
cells grown in six-well plates containing 8 µg/ml protamine sulfate 
(Sigma-Aldrich). After 36 h, the medium was changed to growth 
medium containing 200 ng/ml doxycycline hydrochloride (Alfa Ae-
sar, Ward Hill, MA) and incubated an additional 48 h to induce ex-
pression. Fusion protein expression was determined by presence of 
YFP during live-cell imaging. The pcDNA3-GFP-Rac1(T17N) domi-
nant negative expression construct was purchased from Cell Biolabs 
(San Diego, CA, cat# STA-450) and transfected directly into 92.1 
and Mel202 cells using TransIT-LT1 transfection reagent (MirusBio, 
Wisconsin). Fusion protein expression was determined by the pres-
ence of GFP during live-cell imaging.
Imaging of live cells: transendothelial migration
Polyacrylamide hydrogels were prepared with 0.4% bis-acrylamide 
on glass-bottomed microwell dishes (MatTek, Ashland, MA) as de-
scribed by Onken et al. (2014b). The hydrogels were coated with 
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fibronectin (10 µg/ml in PBS) by incubation at 37°C for 30 min. 
HDMVECs were plated onto the fibronectin-coated hydrogel sub-
strates and incubated overnight to allow formation of monolayers. 
FIGURE 5: BAP1-deficient UM cells show increases in all steps of TEM. (A) Frames from 
time-lapse movies of two independent BAP1(+/–) subclones of the UM 92.1 cell line: 2D3 (upper 
panels and Supplemental Video S5) and 1D7 (lower panels). (B) Endpoint values of cells that 
have undergone each step based on results from three 2-h movies for each cell line. The total 
numbers of cells scored were 395 (parental), 253 (2D3), and 203 (1D7). (C) Maximum rates for 
each step. (D) Times to reach half of the calculated maximum plateaus. Scale bar, 50 µm; 
*p < 0.01.
FIGURE 6: Diagram summarizing UM cell signaling and modes of 
motility during TEM. Constitutively active Gq, the oncogenic driver 
for UM, signals through the dual-GEF TRIO, which activates both 
RhoA and Rac1. Rho signals through ROCK to myosin-II, which 
promotes amoeboid motility. Rac activates PAK and Arp2/3, which 
promote lamellar and lamellipodial protrusions as part of 
mesenchymal motility. The switch from amoeboid to mesenchymal 
motility increases the robustness of TEM, but TEM can occur via a 
solely amoeboid mechanism.
HDMVEC monolayers were allowed to ma-
ture for 3 days before their use in TEM as-
says. Monolayers were inspected by phase-
contrast microscopy to ensure that cells 
covered the substrate completely, without 
defects, before transmigration assays were 
performed, as previously described (Onken 
et al., 2014a,b). Monolayers were rinsed 
with fresh EGM-2 MV media to remove 
floating cells and debris 1 h before assaying 
TEM.
UM cells were trypsinized, collected in 
medium containing FBS to stop tryptic ac-
tivity, and then centrifuged and resus-
pended in EGM-2 MV culture medium at 
105 cells/ml. Inhibitors or vehicle were 
added to individual aliquots of UM cells 2 h 
before TEM imaging, except for FR900359, 
which was added to stock plates 1 day be-
fore imaging (>24 h) and again after harvest-
ing and resuspension in EGM-2 MV. For im-
aging, HDMVEC monolayers were placed in 
an environmental chamber (Stage Top Incu-
bator, Tokai Hit, Shizuoka-ken, Japan) with 
5% CO2 at 37°C on an inverted microscope 
(Olympus IX72) and reassessed visually by 
DIC to identify fields for imaging that were 
absent of defects and showed visible junc-
tions between all endothelial cells.
After monolayer integrity was confirmed, 
104 UM cells were added to the monolayer 
directly over the objective. DIC images were captured at 20-s inter-
vals with a 10× objective. Scoring of TEM events was performed as 
described by Onken et al. (2014a). In DIC images, UM cells are round 
and bright when added to the monolayers (for example, see Supple-
mental Figure S3, 5′). UM cells that interact with the top of the mono-
layer remain bright, even as they bleb and change shape (Supple-
mental Figure S3, 27′). At the initiation of transmigration, UM cells 
send protrusions between cells in the endothelial monolayer, and the 
distal portions of these protrusions become visible beneath the en-
dothelial cells as flat, fanlike projections in DIC images (Supplemen-
tal Figure S3, 32′). The first frame with visible projections is scored as 
the time of “initiation” for the associated UM cell. The transmigrating 
UM cells then expand the opening in the endothelial junction and fill 
the space between the endothelial cells by flattening and becoming 
larger and less bright, resembling the adjacent endothelial cells in 
DIC (Supplemental Figure S3, 50′). The first frame in which the UM 
cell morphology stops changing and the cell settles among endothe-
lial cells is scored as “intercalation.” Later, intercalated UM cells send 
new protrusions that are visible as large flattened projections be-
neath the endothelial cells (Supplemental Figure S3, 89′); the first 
frame in which this projection is visible is scored as “extension.” 
Some UM cells proceed to extend this projection underneath the 
monolayer, expanding and elongating the flattened protrusion. They 
release their adhesions to the endothelial cells opposite the protru-
sion and pull their cell body and nucleus beneath the monolayer, in 
the direction of the leading protrusion (Supplemental Figure S3, 
102′). The first frame in which the UM cell nucleus is completely be-
neath the monolayer is scored as “migration” (Supplemental Figure 
S3, 108′). In the case of treatment with CK-666, UM cells that trans-
migrated directly beneath the monolayer, without intercalating, were 
only scored for “initiation” and “migration.”
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For dominant-negative expression experiments, epifluorescence 
images were collected to detect cells expressing YFP (RhoA-DN) or 
GFP (Rac1-DN) and only positive cells were analyzed by DIC imag-
ing. To control for biological variability among different lots of pri-
mary human endothelial cells, DMSO-treated experiments were 
performed with every inhibitor experiment, and data for each ex-
perimental condition were collected from three separate controlled 
experiments.
Quantification and statistical analysis
Statistical analyses were performed with Prism (GraphPad, San Di-
ego, CA). For endpoint cell counts, the mean and standard error of 
the mean were calculated from at least three experiments for each 
inhibitor, and statistical analysis compared each inhibitor experi-
ment with control experiments from the same day. To generate cu-
mulative percentage curves, data from all experiments for a given 
inhibitor were combined, and these curves were used to quantify 
rates. Nonlinear regression was used to fit curves for each step, 
which extrapolated to maximal completion plateau values used to 
quantify time to half maximal completion. To calculate maximum 
rates, tangent lines were drawn either at the most vertical points of 
curves that showed clear change over time or along the longest 
linear stretch for curves that followed a more linear course. Times 
and rates for each step were normalized to values generated from 
control experiments run on the same day and 90% confidence inter-
vals were calculated.
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